lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

Development and Validation of a Gene Mutation-Based Signature to Predict Response to PD-1 Inhibitors in Non-Squamous NSCLC: A Retrospective Multicohort Study

38 Pages Posted: 12 May 2019

See all articles by Zhong-yi Dong

Zhong-yi Dong

Southern Medical University - Department of Radiation Oncology

Xue Bai

Southern Medical University - Department of Radiation Oncology

Jian Wang

Southern Medical University - Department of Radiation Oncology

Xin-Ran Tang

Southern Medical University - Department of Radiation Oncology

Li Liu

Southern Medical University - Department of Radiation Oncology

Shuai Kang

Southern Medical University - Hepatology Unit

Qiang Fu

Saint Louis University - College for Public Health and Social Justice

Chuan-hui Cao

Southern Medical University - Department of Radiation Oncology

He-san Luo

Southern Medical University - Department of Radiation Oncology

Yu-han Chen

Southern Medical University - Department of Radiation Oncology

Yuan Fang

Southern Medical University - Department of Radiation Oncology

Hong-Bo Zhu

Southern Medical University - Hepatology Unit

Xiu-Ju Du

Southern Medical University - Department of Radiation Oncology

Hao Sun

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

Chao Zhang

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

Hong-Hong Yan

Guangdong Academy of Medical Sciences

Yi-Long Wu

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology

De-Hua Wu

Southern Medical University - Department of Radiation Oncology

More...

Abstract

Background: Genetic variations in non-small cell lung cancer (NSCLC) have been shown potential impact on immune microenvironment, and associated with response or resistance to programmed cell death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an unbiased analysis to develop a gene mutation-based signature (GMS) and predict the response to anti-PD-(L1) therapy.

Methods: In this retrospective multicohort analysis, 316 patients with nonsquamous NSCLC treated with anti-PD-(L1) based therapy from three independent cohorts were included in our study. We developed a risk model named GMS based on the MSK training cohort (n=123). The predictive model was first validated in the separate internal MSK cohort (n=82), and then validated in Checkmate-012 (n=59) and Keynote/SU2C (n=52) external clinical trial cohorts. Tumor samples from the patients were molecularly profiled by MSK or whole exome sequencing.

Findings: A GMS that consisted of 8 genes (TP53, KRAS, STK11, EGFR, PTPRD, KMT2C, SMAD4 and HGF) was generated to classify patients into high and low GMS groups in the training cohort. Patients with high GMS in the training cohort had longer progression-free survival (HR 0·44, 0·30-0·65, p=0·0002) and overall survival (HR 0·56, 0·33-0·94, p=0·0412) compared with low GMS. We noted equivalent findings in the internal validation cohort and in the external validation cohort. The GMS was demonstrated as an independent predictive factor for anti-PD-1(L1) therapy, without affecting the prognosis of non-squamous NSCLC. Meanwhile, GMS showed undifferentiated predictive value in patients with different clinicopathological features. Notably, both GMS and PD-L1 were independent predictors and demonstrated poorly correlated, inclusion of PD-L1 with GMS furtherly improved the predictive capacity for PD-1 blockade immunotherapy.

Interpretation: Our study highlights the potential predictive value of GMS for immunotherapeutic benefit in non-squamous NSCLC. Besides, the combination of GMS and PD-L1 may serve as optimal partner in guiding treatment decisions for anti-PD-(L1) based therapy.

Funding Statement: The National Natural Science Foundation for Young Scientists of China, the Natural Science Foundation of Guangdong Province, and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University.

Declaration of Interests: The authors have no actual or potential conflicts of interest to declare.

Ethics Approval Statement: This study was approved by the Institutional Ethical Review Boards of Nanfang Hospital. Patients provided signed informed consent in accordance with their respective trial protocols or MSK-IMPACT sequencing project.

Keywords: gene mutation-based signature (GMS); non-squamous non-small cell lung cancer; PD-1/PD-L1; predictive; immunotherapy

Suggested Citation

Dong, Zhong-yi and Bai, Xue and Wang, Jian and Tang, Xin-Ran and Liu, Li and Kang, Shuai and Fu, Qiang and Cao, Chuan-hui and Luo, He-san and Chen, Yu-han and Fang, Yuan and Zhu, Hong-Bo and Du, Xiu-Ju and Sun, Hao and Zhang, Chao and Yan, Hong-Hong and Wu, Yi-Long and Wu, De-Hua, Development and Validation of a Gene Mutation-Based Signature to Predict Response to PD-1 Inhibitors in Non-Squamous NSCLC: A Retrospective Multicohort Study (May 8, 2019). Available at SSRN: https://ssrn.com/abstract=3384916

Zhong-yi Dong (Contact Author)

Southern Medical University - Department of Radiation Oncology ( email )

Guangzhou
China

Xue Bai

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Jian Wang

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Xin-Ran Tang

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Li Liu

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Shuai Kang

Southern Medical University - Hepatology Unit

Guangdong
China

Qiang Fu

Saint Louis University - College for Public Health and Social Justice

Saint Louis, MO
United States

Chuan-hui Cao

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

He-san Luo

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Yu-han Chen

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Yuan Fang

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Hong-Bo Zhu

Southern Medical University - Hepatology Unit

Guangdong
China

Xiu-Ju Du

Southern Medical University - Department of Radiation Oncology

Guangzhou
China

Hao Sun

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

China

Chao Zhang

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

China

Hong-Hong Yan

Guangdong Academy of Medical Sciences

Daxuecheng Outer Ring E Rd,
Panyu Qu
Guangzhou Shi, Guangdong Sheng
China

Yi-Long Wu

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology ( email )

China

De-Hua Wu

Southern Medical University - Department of Radiation Oncology ( email )

Guangzhou
China

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
51
Downloads
13